慢性阻塞性肺病急性发作期测定SAA、CRP的意义  

作　　者：陈杰[1] 戴利成[2] 邱东华[1] 何建方[2] 

机构地区：[1]浙江省湖州市中心医院呼吸内科,313000 [2]浙江省湖州市中心医院中心实验室,313000

出　　处：《浙江临床医学》2001年第8期558-559,共2页Zhejiang Clinical Medical Journal

摘　　要：目的 探讨SAA、CRP在慢性阻塞性肺病急性发作期的应用价值。方法 测定50例慢性阻塞性肺病急性发作期患者入院初及治疗后SAA、CRP ,并常规痰标本检查。结果 50例患者入院初及治疗后SAA分别为 (387.2±92.8)ng/ml和 (37.6±29.2)ng/ml,CRP(39.5±22.6)ng/ml和 (22.5±20.7)mg/L ,均有统计学差异 (p<0.001和P<0.002)。50例患者入院初SAA升高49例而CRP升高42例(χ2=4.390,p<0.05)。CRP升高者痰培养阳性仅15例 (36% )。 结论 SAA、CRP可作为慢阻肺急性发作期早期指标及治疗反应指标。Objective To discuss the significance of serum amyloid protein A (SAA) and C-reactive protein (CRP) measurement in acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods SAA and CRP were determined in 50 cases of acute exacerbations of COPD on admission and after treatment. Sputum samples were also examined. Results Both SAA and CRP had significant differences before and after treatment (387.292.8ng/ml vs 37.629.2ng/ml, p<0.001; 39.522.6mg/l vs 22.520.7mg/l, p<0.002). SAA was elevated in 49 cases, but CRP elevation was observed in 42 patients (χ2=4.390, p<0.05). Conclusion SAA and CRP measurement provided early markers for the exacerbation of COPD, and also helped to assess the efficacy of treatment; SAA was more sensitive than CRP.

关 键 词：血清淀粉蛋白 C-反应蛋白 阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]